Back to thiazide-diuretics for hypertension: Reflections after a decade of irrational prescribing

被引：10
作者：
Atle Fretheim
机构：
[1] Dept. of Health Services Research, Norwegian Direct. Hlth./Social Aff.
来源：
BMC Family Practice | / 4卷 / 1期
关键词：
Coronary Heart Disease; Calcium Channel Blocker; Amlodipine; Angiotensin Converting Enzyme Inhibitor; Thiazide;
D O I：
10.1186/1471-2296-4-19
中图分类号：
学科分类号：
摘要：
Background: Whether newer antihypertensive drugs, such as calcium channel blockers, angiotensin converting enzyme inhibitors and a blockers are more effective than thiazides and β blockers in preventing coronary disease, has been debated for years. Discussion: Recently several trials addressing this issue have been finalised, and they provide a convincing answer: the newer drugs are no better than the older ones. In the largest trial to date (ALLHAT), thiazide-type diuretic was found to offer advantages over newer drugs. The medical community should now be capable of reaching consensus, and recommend thiazides as the first line therapy for the treatment of hypertension. Prescribing physicians, cardiologists, drug companies and health authorities are all partly responsible for the years of irrational prescribing that we have witnessed. Summary: All stakeholders should now contribute in order to achieve what is clearly in the public's interest: implementing the use of thiazides in clinical practice.
引用
收藏
页码：1 / 4
页数：3
相关论文
共 27 条
  • [1] Collins R., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., Godwin J., Qizilbash N., Taylor J.O., Hennekens C.H., Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context, Lancet, 335, pp. 827-838, (1990)
  • [2] Kaplan N.M., Antihypertensive drugs: How different classes can impact patients' coronary heart disease risk profile and quality of life, Am J Med, 82, pp. 9-14, (1987)
  • [3] Poulter N., Thom S., Sever P., First line treatment in hypertension, BMJ, 302, (1991)
  • [4] Swales J.D., First line treatment in hypertension, BMJ, 301, pp. 1172-1173, (1990)
  • [5] Brown M.J., Palmer C.R., Castaigne A., De Leeuw P.W., Mancia G., Rosenthal T., Ruilope L.M., Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT), Lancet, 356, pp. 366-372, (2000)
  • [6] Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, pp. 2981-2997, (2002)
  • [7] Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), JAMA, 283, pp. 1967-1975, (2000)
  • [8] Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O., Lanke J., De Faire U., Dahlof B., Karlberg B.E., Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study, Lancet, 356, pp. 359-365, (2000)
  • [9] Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., Luomanmaki K., Dahlof B., De Faire U., Morlin C., Karlberg B.E., Wester P.O., Bjorck J.E., Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, pp. 611-616, (1999)
  • [10] Hansson L., Lindholm L.H., Ekbom T., Dahlof B., Lanke J., Schersten B., Wester P.O., Hedner T., De Faire U., Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study, Lancet, 354, pp. 1751-1756, (1999)
123